Table 4.

List of active non-recruiting trials of PI3K/AKT/mTOR in TNBC.

Phase	Clinical Trial	Treatment	Identifier
3	A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.	Paclitaxel with Atezolizumab and placebo, or Paclitaxel with Ipatasertib and placebo, or combination of Paclitaxel, Atezolizumab, and Ipatasertib, or Paclitaxel with two placebos.	NCT04177108
3	A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer	Paclitaxel with Ipatasertib or placebo	NCT03337724